LB Pharmaceuticals Inc (NASDAQ:LBRX) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of LB Pharmaceuticals Inc (NASDAQ:LBRX) have been assigned an average rating of “Moderate Buy” from the ten ratings firms that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $45.1250.

A number of equities analysts have weighed in on LBRX shares. Wall Street Zen upgraded shares of LB Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Sunday, June 21st. BMO Capital Markets assumed coverage on shares of LB Pharmaceuticals in a research note on Monday, July 20th. They set an “outperform” rating and a $46.00 price target on the stock. Craig Hallum assumed coverage on shares of LB Pharmaceuticals in a report on Friday, April 10th. They issued a “buy” rating and a $36.00 price objective for the company. Roth Capital reiterated a “buy” rating and issued a $37.00 price objective on shares of LB Pharmaceuticals in a research note on Sunday, May 17th. Finally, HC Wainwright reissued a “buy” rating and set a $45.00 target price on shares of LB Pharmaceuticals in a report on Monday.

Institutional Trading of LB Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Spruce Street Capital LP purchased a new position in LB Pharmaceuticals during the 4th quarter valued at about $22,384,000. Jennison Associates LLC lifted its holdings in shares of LB Pharmaceuticals by 11.2% in the fourth quarter. Jennison Associates LLC now owns 821,852 shares of the company’s stock worth $18,294,000 after buying an additional 82,812 shares in the last quarter. Stempoint Capital LP bought a new position in shares of LB Pharmaceuticals in the first quarter valued at approximately $1,233,000. Eversept Partners LP bought a new position in shares of LB Pharmaceuticals in the first quarter valued at approximately $2,471,000. Finally, Calamos Advisors LLC purchased a new position in LB Pharmaceuticals during the first quarter valued at approximately $593,000.

LB Pharmaceuticals News Summary

Here are the key news stories impacting LB Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright raised its FY2026 EPS estimate to a loss of $3.51 from $3.61 and its FY2027 estimate to a loss of $4.87 from $5.30. Quarterly estimates were also improved, including Q3 2026 to a loss of $0.95, Q4 2026 to $1.07, and each quarter of 2027. The revisions indicate better anticipated earnings performance, although LB Pharmaceuticals is still expected to remain unprofitable. HC Wainwright Reaffirms Buy Rating for LB Pharmaceuticals
• Neutral Sentiment: The $45 price target is broadly in line with the stock’s recent trading level, limiting the immediate implied upside from HC Wainwright’s recommendation. The company also continues to carry a negative earnings outlook, with consensus calling for a full-year loss of $3.58 per share.

LB Pharmaceuticals Price Performance

NASDAQ:LBRX opened at $45.03 on Thursday. The company has a market capitalization of $1.29 billion and a P/E ratio of -26.03. The business has a fifty day simple moving average of $32.44 and a two-hundred day simple moving average of $28.21. LB Pharmaceuticals has a 1 year low of $13.36 and a 1 year high of $46.01.

LB Pharmaceuticals (NASDAQ:LBRX) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.67) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.08. As a group, analysts anticipate that LB Pharmaceuticals will post -3.55 earnings per share for the current year.

About LB Pharmaceuticals

We are a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. We are building a pipeline that leverages the broad therapeutic potential of our lead product candidate, LB-102, which we believe has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries, not including the United States, because the development and regulatory requirements of the U.S.